Skip to main content
PMC home page
Oncology Letters logoLink to Oncology Letters
. 2017 Jul 20;14(3):3705–3710. doi: 10.3892/ol.2017.6617

Comparison of the protein expression of calpain-1, calpain-2, calpastatin and calmodulin between gastric cancer and normal gastric mucosa

Bide Liu 1, Yu Zhou 1, Dan Lu 2,3, Yong Liu 4, Si-Quan Zhang 1, Yan Xu 2, Wei Li 1,3,✉, Xiao Gu 2,3,✉
PMCID: PMC5588046  PMID: 28927135

Abstract

The understanding of molecular mechanisms that are involved in the development and the progression of gastric cancer (GC) are of importance for the diagnosis and treatment. The calpain system, which contains the calpains and the endogenous inhibitor, has been suggested as an important factor in the tumorigenesis and migration of colorectal adenocarcinoma, breast and ovarian cancer, and as a prognostic marker for GC. However, the expression level of calpain system proteins in GC and normal-appearing peritumoral gastric mucosa remain unknown. The present study investigated the expression of calpain-1 (CAPN1), calpain-2 (CAPN2), calpastatin and calmodulin (CaM) in GC and uninvolved gastric mucosa tissues with immunohistochemistry. Results demonstrated that CAPN2 protein level increased in GCs compared with normal tissues, while calpastatin and CaM protein level decreased. No evident alterations were observed for CAPN1. Although the protein expression of all these four proteins was not in association with the clinical variables of GC in the present study, higher calpain enzyme activity could be a negative prognostic marker, since calpains are responsible for the generation of active forms of certain proteins that facilitate the progression of cancer. The ratio of (CAPN1 × CAPN2)/(calpastatin × CaM) may serve as a potential index for diagnosis of GC.

Keywords: gastric cancer, calpain-1, calpain-2, calpastatin, calmodulin

Introduction

Gastric cancer (GC) remains a major public health problem, since it was the fourth most common type of cancer and the third most common cause of cancer-associated mortality worldwide in 2012 (1). In China, GC is the third frequently diagnosed cancer and the third leading cause of cancer-associated mortality in 2011 (2). The understanding of molecular mechanisms involved in the development and the progression of GC is important for the diagnosis and treatment of this disease.

Calpains are a group of calcium-activated, non-lysosomal neutral cysteine proteases (3). At present, the best-characterized calpain isoforms are calpain-1 (µ-calpain or CAPN1) and calpain-2 (m-calpain or CAPN2), which require µM and mM concentrations of Ca2+ for their intracellular activity, respectively (3). CANP1 and CAPN2 are composed of a distinct large catalytic subunit (80 kDa) and a small common regulatory subunit (28 kDa) (3). Calpains are responsible for the cleavage of a broad spectrum of protein substrates, resulting in the generation of functional fragments rather than total degradation products (4,5). It has been confirmed that calpains are involved in cell differentiation, migration and transformation, and perform an important role in cancer pathogenesis and progression (4,6,7).

The proteolytic activity of calpain is inhibited by an endogenous inhibitor, calpastatin, in a substrate-competitive manner (8). The expression level of calpastatin directly effects the calpain activity (9). In addition, calmodulin (CaM) is another endogenous regulator of proteolytic activity of calpains (10). By binding to the PEST sequence [a sequence that is rich in proline (P), glutamic acid (E), serine (S) and threonine (T)], which is the target sequence of calpain, CaM protects the protein to be cleaved by calpain (11–14).

The role that calpain system performs in cancer is complicated. Calpain has been reported to be involved in apoptosis of cancer cells (15). In addition, the upregulation of calpain may be involved in cancer development and migration (16), and calpain expression is upregulated in a number of tumors, including colorectal adenocarcinoma (17), breast cancer (18) and ovarian cancer (19). In GC, it has been reported that the calpain activity was upregulated compared with normal tissue (20), and it is speculated that higher calpain and calpastatin expression may be a favorable prognostic marker for GC (21). However, there is still no direct experimental data about the comparison of the protein expression levels of the members of calpain system in GC and normal gastric mucosa.

In order to understand the roles that calpain, calpastatin and CaM serve in GC, the current study compared the expression levels of CAPN1, CAPN2, calpastatin and CaM in human GC tissues and normal glandular tissues with immunohistochemistry. The present results demonstrated that CAPN2 protein level increased in GC compared with normal tissue, while calpastatin and CaM protein level decreased. Calpain-1 appeared unchanged. None of the protein expression levels were found to be associated with the clinical variables of GC in the present study. The ratio of (CAPN1 × CAPN2)/(calpastatin × CaM) best predicted GC.

Materials and methods

Materials

Polyclonal antibodies specific for CANP1 (dilution, 1:1,000; cat no. PA5-27681), CAPN2 (dilution, 1:1,000; PA5-27720) and CaM (cat no. MA3-917; 1:20) were obtained from Thermo Fisher Scientific, Inc. (Waltham, MA, USA) and anti-calpastatin (cat no. sc-20779; 1:500) was purchased from Santa Cruz Biotechnology, Inc. (Dallas, TX, USA). Immunol Staining Primary Antibody Diluent Buffer and Hematoxylin were from Nanjing KeyGen Biotech Co., Ltd. (Nanjing, China). UltraSensitive™ S-P kit and 3,3′-diaminobenzidine (DAB) kit were purchased from Fuzhou Maixin Biotech Co., Ltd. (Fuzhou, China).

Clinical samples

Cancerous tissues and normal peritumoral gastric mucosa (5 cm away from the tumor) were collected from patients (n=51) treated at Northern Jiangsu People's Hospital (Yangzhou, China) between January 2014 and December 2015. The age and gender distribution, and the clinicopathological variables of the patients are summarized in Table I. The study design was approved by the local ethics committee of Northern Jiangsu People's Hospital, in accordance with the guidelines of the 1975 Declaration of Helsinki. Written informed consent was obtained from all patients. Surgical pathology specimens of 51 patients with GC who had undergone resection were collected directly from surgery and fixed in formalin (10%) immediately at 4°C for 24 h. Normal-appearing peritumoral gastric mucosa was similarly dissected and fixed.

Table I.

Clinicopathological variables of patient sample.

Variables Patients, n
Age, years (mean ± SD) 62.5±10.1
Gender
  Male 41
  Female 10
Tumor size, cm3 (mean ± SD) 6.4±1.6
T classification
  1   1
  2   6
  3 39
  4   5
N classification
  0 10
  1 16
  2 20
  3   5
Clinical stage
  I   1
  II   7
  IIIa 16
  IIIb 20
  IV   7
Open in a new tab

(n=51). SD, standard deviation; T, tumor; N, node.

Immunohistochemistry

Sections (4 µm) of the formalin-fixed, paraffin-embedded tissues were cut, followed by deparaffinizing in xylene and rehydrating in an alcohol gradient. Antigen retrieval was performed in citrate buffer (pH 6.0) using an electric pressure cooker for 2 min at 120°C, and cooled naturally in the buffer for ~20 min. Immunostaining was performed according to the streptavidin-peroxidase method using a kit (Nanjing KeyGen Biotech Co., Ltd.) according to the manufacturer's protocol. Subsequent to blocking of the samples with blocking solution in the kit, the primary antibodies anti-CAPN1 (dilution, 1:1,000; cat no. PA5-27681; Thermo Fisher Scientific, Inc.), anti-CAPN2 (dilution, 1:1,000; cat no. PA5-27720; Thermo Fisher Scientific, Inc.), anti-calpastatin (dilution, 1:500; cat no. sc-20779; Santa Cruz Biotechnology, Inc.) and anti-CaM (1:20; cat no. MA3-917; Thermo Fisher Scientific, Inc.) were diluted using primary antibody diluents and applied to the tissues at 4°C overnight. Staining was achieved using the DAB dye for 1 min at 25°C.

The staining was observed with an upright microscope (magnification, ×40, 10 fields of view/slice) equipped with a CCD camera (Olympus Corporation, Tokyo, Japan). The images were document with cellSens Entry software (Ver. 1.5; Olympus Corporation, Tokyo, Japan). The expression of the four proteins was quantified by mean optical density (MOD) using Image-Pro Plus 6.0 software (Media Cybernetics, Inc., Rockville, MD, USA).

Statistical analysis

The results were presented as mean ± standard deviation. Based on whether the distribution was normal or not, paired t-test or Wilcoxon matched-pairs signed rank test were used to compare the MOD variance in cancer and its peritumoral normal mucosa tissues. The association between calpain system protein expressions with each other was subjected to Pearson's rank correlation. Receiver operator characteristic (ROC) curves were used to investigate which protein could be the best indicator for GC, and the cut-off points were generated according to ROC curve and Youden's index. The association between protein expression and clinicopathological variables was assessed using unpaired t-test (gender) and Spearman's rank correlation (other parameters). P<0.05 was considered to indicate a statistically significant difference. Statistical analysis was performed using SPSS 17.0 software (SPSS, Inc., Chicago, IL, USA).

Results

Stain location and frequency

CAPN1, CAPN2, calpastatin and CaM demonstrated cytoplasmic staining, with a certain degree of heterogeneity within samples. Typical staining patterns are shown in Fig. 1. In normal tissues, CAPN1 had a median MOD value of 2.7×10−2, and ranged between 2.9×10−3 to 6.1×10−2; CAPN2 had a median MOD value of 5.0×10−2 and ranged between 1.8×10−2 to 1.1×10−1; calpastatin had a median MOD value of 3.3×10−2 and ranged between 1.9×10−3 to 9.1×10−2; and CaM had a median MOD of 1.2×10−2 and ranged between 2.0×10−8 to 8.1×10−2. In GC tissues, CAPN1 had a median MOD value of 3.2×10−2 and ranged between 3.2×10−3 to 1.4×10−1; CAPN2 had a median MOD value of 8.1×10−2 and ranged between 2.0×10−2 to 1.4×10−1; calpastatin had a median MOD value of 1.7×10−2 and ranged between 2.8×10−3 to 6.6×10−2; and CaM had a median MOD of 1.6×10−3 and ranged between 1.0×10−8 to 4.3×10−2. Paired t-test demonstrated that calpain-2 exhibited higher scores in GC compared with the normal tissue (Fig. 2B), while the expression of calpastatin and CaM decreased in cancer tissues (Fig. 2C and D). Wilcoxon matched-pairs signed rank test indicated that the expression of calpain-1 exhibited no difference in GC tissues against gastric mucosa (Fig. 2A). The association between the expression of the proteins with each other was assessed using the Pearson's rank correlation coefficient. As exhibited in Table II, in GC tissues, the expression of CAPN1, CAPN2, calpastatin and CaM proteins significantly correlated with each other (P<0.05), though these correlations were weak. In normal-appearing peritumoral gastric mucosa, the expression of these four proteins also correlated with each other. The expression of calpastatin exhibited a stronger correlated with calpain-1 (r=0.741; P<0.001), while that of the others were weak.

Figure 1.

Figure 1.

Open in a new tab

Representative photomicrographs of proteins expression levels. (A) CAPN1 expression in normal tissue. (B) CAPN1 expression in GC tissue. (C) CAPN2 expression in normal tissue. (D) CAPN2 expression in GC tissue. (E) Calpastatin expression in normal tissue. (F) Calpastatin expression in GC tissue. (G) CaM expression in normal tissue. (H) CaM expression in GC tissue. Photomicrographs are at ×40 magnification, where the scale bar shows 50 µm. GC, gastric cancer; CaM, calmodulin.

Figure 2.

Figure 2.

Open in a new tab

(A) CAPN1, (B) CAPN2, (C) calpastatin and (D) CaM protein expression levels (exhibited as MOD) in gastric cancer and normal tissues (n=51). ***P<0.0001. MOD, mean optical density; CaM, calmodulin.

Table II.

The correlation between expression of the proteins in normal-appearing peritumoral gastric mucosa and cancer tissue with each other.

Normal tissue Cancer tissue
Protein Pearson value P-value Pearson value P-value
Calpain-1 with calpaspatin 0.741 <0.0001 0.342 0.014
Calpain-2 with calpaspatin 0.535 <0.0001 0.553 <0.0001
CaM with calpaspatin 0.551 <0.0001 0.396 0.004
Calpain-1 with calpain-2 0.419 0.002 0.441 0.001
Calpain-1 with CaM 0.443 0.001 0.428 0.002
Calpain-2 with CaM 0.402 0.003 0.401 0.004
Open in a new tab

CaM, calmodulin.

Decisions

ROC curves

ROC curves were employed to determine whether the calpain system proteins are potential GC specific biomarkers. Area under the curve (AUC) of ROC curves, cut-off points and positive likelihood ratio were generated (Table III). Among the four proteins, CaM appeared to be the best discriminating marker for GC (AUC=83.2%). Since the calpain activity is regulated by calpastatin and the activity modulator CaM, the ratios of calpains to the regulators were also investigated (Table III). The results demonstrated that when the ratios of these protein levels were used, the AUCs of ROC curves increased. The MOD value ratio of (CAPN1 xCAPN2)/(calpastatin × CaM) demonstrated the best discrimination power (AUC=89.7%) compared with the situation when single protein expression was used (Table III). Since the ratio of (CAPN1 × CAPN2)/(calpastatin × CaM) may better reflect the calpain activity, calpain activity has the potential to be developed as a new diagnostic indicator for GC.

Table III.

Cut-off points, sensitivity, specificity and AUC of ROC.

Protein Cut-off point Sensitivity, % Specificity, % LR AUC of ROC, %
CAPN1 0.056 25.49 94.12 4.33 56.56
CAPN2 0.077 52.94 92.16 6.75 75.24
Calpastatin 0.022 86.27 66.67 2.59 76.78
CaM 0.007 72.55 86.27 5.29 83.22
CAPN1 × CAPN2/(CaM × calpastatin) 25.000 84.31 86.27 6.14 89.73
Open in a new tab

AUC, area under the curve; CAPN1, calpain-1; CAPN2, calpain-2; CaM, calmodulin; ROC, receiver operator characteristic; LR, likelihood ratio.

Association with clinicopathological criteria

The expression levels of CAPN1, CAPN2, calpastatin and CaM were assessed for their correlation with a number of clinicopathological variables, including age, gender, tumor size, postoperative pathological stage and clinicopathological stage (cTNM) (Table IV). None of the proteins investigated in GC or normal tissues showed significant correlation with the clinicopathological variables.

Table IV.

Association between calapin-1, calpain-2, calpastatin and CaM protein expression and clinicopathological variables.

Calpain-1 Calpain-2 Calpastatin CaM
Parameter Normal Cancer Normal Cancer Normal Cancer Normal Cancer
Gender 0.333 0.439 0.780 0.348 0.159 0.678 0.051 0.719
Age 0.861 0.466 0.534 0.161 0.111 0.417 0.938 0.447
Size 0.376 0.946 0.479 0.519 0.330 0.619 0.122 0.134
T 0.253 0.767 0.115 0.413 0.209 0.869 0.135 0.962
N 0.873 0.391 0.333 0.332 0.752 0.185 0.711 0.124
cTNM 0.285 0.926 0.051 0.418 0.215 0.454 0.627 0.590
Open in a new tab

P-values were resultant from unpaired t test (gender) and Spearman's rank correlation (other parameters). No significant P-values were found. CaM, calmodulin; cTNM, clinicopathological stage; T, tumor; N, node.

Discussion

The current study investigated the expression of four calpain system proteins, CAPN1, CAPN2, calpastatin and CaM between GC vs. uninvolved mucosa tissues. The expression level of CAPN2 was higher in GC tissues, while the levels of calpastatin and CaM, which inhibit calpain activity, were higher in uninvolved mucosa tissues. However, CAPN1 protein levels were similar in the two tissues. The alteration of these protein expression levels is in accordance with previous enzyme activity investigation 20). In addition, the alteration of calpain system protein levels was also observed in other types of cancer. In colorectal adenocarcinomas, similar to our results in GC, upregulation of CAPN2 and downregulation of calpastatin was observed (17). In human prostate cancer, the mRNA level of CAPN1 increased (22). These results suggested that calpains may be an important factor in tumorigenesis and tumor progression, and higher calpain enzyme activity may be a negative prognostic marker. Studies demonstrated that calpains were responsible for the generation of active forms of proteins that facilitate the progress of cancer: In breast cancer, calpain was associated with the cleavage of human epidermal growth factor receptor 2 (23) and E-cadherin (24), and the two products were responsible for the progression of cancer. In prostate cancer, calpain was hypothesized to be responsible for the generation of active androgen receptor cleavage form (25). In accordance, high-level calpain indicates poor clinical outcome in human breast cancer (18,26). However, in GC Storr et al reported that high level of CAPN1, CAPN2 and calpastatin each indicated a favorable clinical outcome (21). According to the present results, the expression of calpastatin was in positive correlation with calpain in GC. The correlation between the protein level of calpain and its endogenous inhibitor, calpastatin, may be reason that the clapains and its inhibitor, which exert opposite functions, both indicated a favorable prognostic result of GC. Since calpain activity in the prognostic investigation is unknown, whether the higher calpain activity performs a favorable role in GC requires additional investigation.

To explore whether calpains and their associated proteins may be used as biomarkers that possess diagnostic and treatment potentials, ROC curves were employed in the present study. According to the AUCs (Table III), when using a single protein, CaM provides the best prediction (AUC =83.2%). In addition, the four proteins in combination, (CAPN1 × CAPN2)/(calpastatin × CaM), improved the prediction ability (AUC =89.7%). Since the ratio of (CAPN1 × CAPN2)/(calpastatin × CaM) may better reflect the calpain activity, the present results suggest that intra-tumor calpain activity may provide a potential biomarker for GC. It has been reported that calpain was responsible for platelet secretion (27). Galectin-3 secretion is also dependent on the calpain activity (28). In addition, calpain itself can be secreted by tubular epithelial cells (29). Thus, detecting serum secreted calpain or screening serum secreting proteins direct or indirect regulated by calpain may provide a new diagnostic target.

The protein expression levels of intra-tumor or normal-appearing gastric mucosal calpain system showed no correlation with various clinicopathological variables, including gender, age, tumor size, T category, N category or cTNM. These results are different from Storr's study (21). Whether this system is correlated with the clinicopathological variables requires additional investigation.

In conclusion, calpain may be a positive factor in tumorigenesis and tumor progression. Although the protein expression of all these four proteins was not in association with the clinical variables of GC in the present study, higher calpain enzyme activity may be a negative prognostic marker, since calpains are responsible for the generation of active forms of certain proteins that facilitate the progression of cancer. The ratio of (CAPN1 × CAPN2)/(calpastatin × CaM) may serve as a potential biomarker for GC.

Acknowledgements

The present study was supported by the National Natural Foundation of China (grant no. 81102460), the College Natural Foundation of Jiangsu Education Department (grant no. 14KJB310026), the Yangzhou Natural Foundation (grant no. YZ2014020), the Fundamental Research Funds for the Central Universities and the Yangzhou University Fundamental Research Funds.

References

  • 1.Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87–108. doi: 10.3322/caac.21262. [DOI] [PubMed] [Google Scholar]
  • 2.Chen W, Zheng R, Zeng H, Zhang S, He J. Annual report on status of cancer in China, 2011. Chin J Cancer Res. 2015;27:2–12. doi: 10.1186/s40880-015-0001-2. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Moretti D, Del Bello B, Allavena G, Maellaro E. Calpains and cancer: Friends or enemies? Arch Biochem Biophys. 2014;564:26–36. doi: 10.1016/j.abb.2014.09.018. [DOI] [PubMed] [Google Scholar]
  • 4.Carragher NO, Frame MC. Calpain: A role in cell transformation and migration. Int J Biochem Cell Biol. 2002;34:1539–1543. doi: 10.1016/S1357-2725(02)00069-9. [DOI] [PubMed] [Google Scholar]
  • 5.Sorimachi H, Hata S, Ono Y. Impact of genetic insights into calpain biology. J Biochem. 2011;150:23–37. doi: 10.1093/jb/mvr070. [DOI] [PubMed] [Google Scholar]
  • 6.Huang Y, Wang KK. The calpain family and human disease. Trends Mol Med. 2001;7:355–362. doi: 10.1016/S1471-4914(01)02049-4. [DOI] [PubMed] [Google Scholar]
  • 7.Storr SJ, Carragher NO, Frame MC, Parr T, Martin SG. The calpain system and cancer. Nat Rev Cancer. 2011;11:364–374. doi: 10.1038/nrc3050. [DOI] [PubMed] [Google Scholar]
  • 8.Huang Z, Hoffmann FW, Norton RL, Hashimoto AC, Hoffmann PR. Selenoprotein K is a novel target of m-calpain, and cleavage is regulated by Toll-like receptor-induced calpastatin in macrophages. J Biol Chem. 2011;286:34830–34838. doi: 10.1074/jbc.M111.265520. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Li X, Li Y, Shan L, Shen E, Chen R, Peng T. Over-expression of calpastatin inhibits calpain activation and attenuates myocardial dysfunction during endotoxaemia. Cardiovasc Res. 2009;83:72–79. doi: 10.1093/cvr/cvp100. [DOI] [PubMed] [Google Scholar]
  • 10.Marshall CB, Nishikawa T, Osawa M, Stathopulos PB, Ikura M. Calmodulin and STIM proteins: Two major calcium sensors in the cytoplasm and endoplasmic reticulum. Biochem Biophys Res Commun. 2015;460:5–21. doi: 10.1016/j.bbrc.2015.01.106. [DOI] [PubMed] [Google Scholar]
  • 11.Barnes JA, Gomes AV. PEST sequences in calmodulin-binding proteins. Mol Cell Biochem. 1995;149–150:17–27. doi: 10.1007/BF01076559. [DOI] [PubMed] [Google Scholar]
  • 12.Sivanandam A, Murthy S, Chinnakannu K, Bai VU, Kim SH, Barrack ER, Menon M, Reddy GP. Calmodulin protects androgen receptor from calpain-mediated breakdown in prostate cancer cells. J Cell Physiol. 2011;226:1889–1896. doi: 10.1002/jcp.22516. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Molinari M, Anagli J, Carafoli E. PEST sequences do not influence substrate susceptibility to calpain proteolysis. J Biol Chem. 1995;270:2032–2035. doi: 10.1074/jbc.270.5.2032. [DOI] [PubMed] [Google Scholar]
  • 14.Wang KK, Villalobo A, Roufogalis BD. Calmodulin-binding proteins as calpain substrates. Biochem J. 1989;262:693–706. doi: 10.1042/bj2620693. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Yang H, Murthy S, Sarkar FH, Sheng S, Reddy GP, Dou QP. Calpain-mediated androgen receptor breakdown in apoptotic prostate cancer cells. J Cell Physiol. 2008;217:569–576. doi: 10.1002/jcp.21565. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Liu T, Mendes DE, Berkman CE. Prolonged androgen deprivation leads to overexpression of calpain 2: Implications for prostate cancer progression. Int J Oncol. 2014;44:467–472. doi: 10.3892/ijo.2013.2196. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Lakshmikuttyamma A, Selvakumar P, Kanthan R, Kanthan SC, Sharma RK. Overexpression of m-calpain in human colorectal adenocarcinomas. Cancer Epidemiol Biomarkers Prev. 2004;13:1604–1609. [PubMed] [Google Scholar]
  • 18.Storr SJ, Lee KW, Woolston CM, Safuan S, Green AR, Macmillan RD, Benhasouna A, Parr T, Ellis IO, Martin SG. Calpain system protein expression in basal-like and triple-negative invasive breast cancer. Ann Oncol. 2012;23:2289–2296. doi: 10.1093/annonc/mds176. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Storr SJ, Safuan S, Woolston CM, Abdel-Fatah T, Deen S, Chan SY, Martin SG. Calpain-2 expression is associated with response to platinum based chemotherapy, progression-free and overall survival in ovarian cancer. J Cell Mol Med. 2012;16:2422–2428. doi: 10.1111/j.1582-4934.2012.01559.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Ivanova EV, Kondakova IV, Spirina LV, Afanas'ev SG, Avgustinovich AV, Cheremisina OV. Chymotrypsin-like activity of proteasomes and total calpain activity in gastric and colorectal cancer. Bull Exp Biol Med. 2014;157:781–784. doi: 10.1007/s10517-014-2666-y. [DOI] [PubMed] [Google Scholar]
  • 21.Storr SJ, Pu X, Davis J, Lobo D, Reece-Smith AM, Parsons SL, Madhusudan S, Martin SG. Expression of the calpain system is associated with poor clinical outcome in gastro-oesophageal adenocarcinomas. J Gastroenterol. 2013;48:1213–1221. doi: 10.1007/s00535-012-0743-4. [DOI] [PubMed] [Google Scholar]
  • 22.Rios-Doria J, Day KC, Kuefer R, Rashid MG, Chinnaiyan AM, Rubin MA, Day ML. The role of calpain in the proteolytic cleavage of E-cadherin in prostate and mammary epithelial cells. J Biol Chem. 2003;278:1372–1379. doi: 10.1074/jbc.M208772200. [DOI] [PubMed] [Google Scholar]
  • 23.Panis C, Pizzatti L, Corrêa S, Binato R, Lemos GF, Herrera AC, Seixas TF, Cecchini R, Abdelhay E. The positive is inside the negative: HER2-negative tumors can express the HER2 intracellular domain and present a HER2-positive phenotype. Cancer Lett. 2015;357:186–195. doi: 10.1016/j.canlet.2014.11.029. [DOI] [PubMed] [Google Scholar]
  • 24.Ye Y, Tian H, Lange AR, Yearsley K, Robertson FM, Barsky SH. The genesis and unique properties of the lymphovascular tumor embolus are because of calpain-regulated proteolysis of E-cadherin. Oncogene. 2013;32:1702–1713. doi: 10.1038/onc.2012.180. [DOI] [PubMed] [Google Scholar]
  • 25.Libertini SJ, Tepper CG, Rodriguez V, Asmuth DM, Kung HJ, Mudryj M. Evidence for calpain-mediated androgen receptor cleavage as a mechanism for androgen independence. Cancer Res. 2007;67:9001–9005. doi: 10.1158/0008-5472.CAN-07-1072. [DOI] [PubMed] [Google Scholar]
  • 26.Storr SJ, Woolston CM, Barros FF, Green AR, Shehata M, Chan SY, Ellis IO, Martin SG. Calpain-1 expression is associated with relapse-free survival in breast cancer patients treated with trastuzumab following adjuvant chemotherapy. Int J Cancer. 2011;129:1773–1780. doi: 10.1002/ijc.25832. [DOI] [PubMed] [Google Scholar]
  • 27.Croce K, Flaumenhaft R, Rivers M, Furie B, Furie BC, Herman IM, Potter DA. Inhibition of calpain blocks platelet secretion, aggregation, and spreading. J Biol Chem. 1999;274:36321–36327. doi: 10.1074/jbc.274.51.36321. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Menon S, Kang CM, Beningo KA. Galectin-3 secretion and tyrosine phosphorylation is dependent on the calpain small subunit, Calpain 4. Biochem Biophys Res Commun. 2011;410:91–96. doi: 10.1016/j.bbrc.2011.05.112. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Peltier J, Bellocq A, Perez J, Doublier S, Dubois YC, Haymann JP, Camussi G, Baud L. Calpain activation and secretion promote glomerular injury in experimental glomerulonephritis: Evidence from calpastatin-transgenic mice. J Am Soc Nephrol. 2006;17:3415–3423. doi: 10.1681/ASN.2006050542. [DOI] [PubMed] [Google Scholar]

Articles from Oncology Letters are provided here courtesy of Spandidos Publications

RESOURCES